Skip to main content
Fig. 2 | Journal of Translational Medicine

Fig. 2

From: A strategy to protect off-the-shelf cell therapy products using virus-specific T-cells engineered to eliminate alloreactive T-cells

Fig. 2

Growth of CMV virus specific T-cells (CMVSTs) expressing the CHAR molecule. a CMVSTs were retrovirally transduced with the CHAR construct and stained for CD34 on Day 4 after transduction. b Growth curves showing expansion of CMVSTs after transduction with the CHAR molecule (mean ± SEM, n = 3). c Design of inducible CHAR construct (iCHAR). d CMVSTs expressing the iCHAR were incubated either with Doxycycline or without for 24 h and stained for CD34. Gate set based off of NT conditions. e Fold expansion of CMVSTs after transduction with the iCHAR molecule (mean ± SEM, n = 3). hPGK human PGK promoter, TRE3GS tet response element

Back to article page